|
[1]
|
Loke, J., Malladi, R., Moss, P. and Craddock, C. (2019) The Role of Allogeneic Stem Cell Transplantation in the Management of Acute Myeloid Leukaemia: A Triumph of Hope and Experience. British Journal of Haematology, 188, 129-146. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Sterling, C. and Webster, J. (2020) Harnessing the Immune System after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia. American Journal of Hematology, 95, 529-547. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Falini, B. and Martelli, M.P. (2023) Comparison of the International Consensus and 5th WHO Edition Classifications of Adult Myelodysplastic Syndromes and Acute Myeloid Leukemia. American Journal of Hematology, 98, 481-492. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Rausch, C., Rothenberg-Thurley, M., Dufour, A., Schneider, S., Gittinger, H., Sauerland, C., et al. (2023) Validation and Refinement of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia. Leukemia, 37, 1234-1244. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Leukemia & Lymphoma Group, Chinese Society of Hematology and Chinese Medical Association (2021) [Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (Not APL) (2021)]. Chinese Journal of Hematology, 42, 617-623.
|
|
[6]
|
Sauerer, T., Velázquez, G.F. and Schmid, C. (2023) Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Immune Escape Mechanisms and Current Implications for Therapy. Molecular Cancer, 22, Article No. 180. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Mohty, R., El Hamed, R., Brissot, E., Bazarbachi, A. and Mohty, M. (2023) New Drugs Before, During, and after Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia. Haematologica, 108, 321-341. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Kinsella, F.A.M., Maroto, M.A.L., Loke, J. and Craddock, C. (2024) Strategies to Reduce Relapse Risk in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukaemia. British Journal of Haematology, 204, 2173-2183. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Lin, C.H., Chen, T.C., Shih, Y.H., et al. (2022) Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution. Journal of International Medical Research, 50. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Abou Dalle, I., Labopin, M., Kröger, N., Schroeder, T., Finke, J., Stelljes, M., et al. (2023) Impact of Disease Burden on Clinical Outcomes of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 58, 784-790. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Wienecke, C.P., Heida, B., Venturini, L., Gabdoulline, R., Krüger, K., Teich, K., et al. (2024) Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation. Blood, 144, 296-307. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Short, N.J., Fu, C., Berry, D.A., Walter, R.B., Freeman, S.D., Hourigan, C.S., et al. (2022) Association of Hematologic Response and Assay Sensitivity on the Prognostic Impact of Measurable Residual Disease in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Leukemia, 36, 2817-2826. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Buckley, S.A., Wood, B.L., Othus, M., Hourigan, C.S., Ustun, C., Linden, M.A., et al. (2017) Minimal Residual Disease Prior to Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Meta-Analysis. Haematologica, 102, 865-873. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Moukalled, N., Labopin, M., Versluis, J., Socié, G., Blaise, D., Salmenniemi, U., et al. (2024) Complex Karyotype But Not Other Cytogenetic Abnormalities Is Associated with Worse Posttransplant Survival of Patients with Nucleophosmin 1‐mutated Acute Myeloid Leukemia: A Study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. American Journal of Hematology, 99, 360-369. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Peric, Z., Wilson, J., Durakovic, N., Ostojic, A., Desnica, L., Vranjes, V.R., et al. (2018) Early Human Cytomegalovirus Reactivation Is Associated with Lower Incidence of Relapse of Myeloproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow Transplantation, 53, 1450-1456. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Turki, A.T., Tsachakis-Mück, N., Leserer, S., Crivello, P., Liebregts, T., Betke, L., et al. (2021) Impact of CMV Reactivation on Relapse of Acute Myeloid Leukemia after HCT Is Dependent on Disease Stage and ATG. Blood Advances, 6, 28-36. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Teira, P., Battiwalla, M., Ramanathan, M., Barrett, A.J., Ahn, K.W., Chen, M., et al. (2016) Early Cytomegalovirus Reactivation Remains Associated with Increased Transplant-Related Mortality in the Current Era: A CIBMTR Analysis. Blood, 127, 2427-2438. [Google Scholar] [CrossRef] [PubMed]
|